U.S. markets closed

AgeX Therapeutics, Inc. (AGE)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.2200-0.0100 (-0.45%)
At close: 4:00PM EST

2.2200 0.00 (0.00%)
After hours: 5:36PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close2.2300
Open2.2000
Bid2.0200 x 1200
Ask2.2800 x 1800
Day's Range2.0800 - 2.2800
52 Week Range0.6660 - 3.9300
Volume296,588
Avg. Volume333,466
Market Cap83.674M
Beta (5Y Monthly)1.47
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement
    Business Wire

    AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

    AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. ("LyGenesis"), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement for a merger of the two companies. LyGenesis recently received U.S. Food and Drug Administration clearance for its Investigational New Drug application to conduct a Phase 2a clinical trial on the safety, tolerability, and efficacy of its lead cell therapy for patients with end-stage liver disease, with study initiation planned for 2021. The combined company’s pipeline would also include thymus, pancreas, and kidney regeneration, in addition to the existing AgeX assets, including UniverCyte™, which uses the HLA-G gene to potentially confer low immune observability to cells to suppress rejection of transplanted cells.

  • AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only
    Business Wire

    AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

    AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting of Stockholders (the "Annual Meeting") to be held at 10:00 a.m. Pacific Standard Time on Monday, December 28, 2020 will be permitted only through online participation. The County of Alameda, California, where AgeX’s offices are located and where AgeX had planned to hold the Annual Meeting, has issued Health Officer Order 20-21 (the "Order") restricting or prohibiting many business activities due to the COVID-19 pandemic. The Order provides that offices must close and business must be conducted remotely, except in critical infrastructure sectors where remote work is not possible.

  • AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
    Business Wire

    AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

    AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, reported financial and operating results for the third quarter ended September 30, 2020.